Need Help?

Primary Neuroblastoma Circle-seq Data

Circle-seq data for 21 primary neuroblastoma samples supporting Koche et al. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma (2020).

Request Access

Data access policy for primary neuroblastoma Circle-seq

1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify Dr. Anton Henssen within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify Dr. Anton Henssen prior to any significant changes to the protocol for the Project. 14. The User Institution will notify Dr. Anton Henssen as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. Dr. Anton Henssen may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than Dr. Anton Henssen. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of Germany and shall be subject to the exclusive jurisdiction of the German courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001004797 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00004838621 bam 465.9 MB
EGAF00004838622 bam 474.0 MB
EGAF00004838623 bam 470.1 MB
EGAF00004838624 bam 563.8 MB
EGAF00004838625 bam 320.0 MB
EGAF00004838626 bam 365.2 MB
EGAF00004838627 bam 814.9 MB
EGAF00004838628 bam 689.2 MB
EGAF00004838629 bam 396.7 MB
EGAF00004838630 bam 174.2 MB
EGAF00004838631 bam 163.7 MB
EGAF00004838632 bam 363.1 MB
EGAF00004838633 bam 932.0 MB
EGAF00004838634 bam 315.9 MB
EGAF00004838635 bam 561.9 MB
EGAF00004838636 bam 813.2 MB
EGAF00004838637 bam 746.3 MB
EGAF00004838638 bam 518.5 MB
EGAF00004838639 bam 931.9 MB
EGAF00004838640 bam 1.1 GB
EGAF00004838641 bam 672.3 MB
EGAF00004838642 fastq.gz 1.9 GB
EGAF00004838643 fastq.gz 1.9 GB
EGAF00004838644 fastq.gz 2.4 GB
EGAF00004838645 fastq.gz 2.4 GB
EGAF00004838646 fastq.gz 1.8 GB
EGAF00004838647 fastq.gz 1.8 GB
EGAF00004838648 fastq.gz 1.6 GB
EGAF00004838649 fastq.gz 1.5 GB
EGAF00004838650 fastq.gz 1.9 GB
EGAF00004838651 fastq.gz 1.8 GB
EGAF00004838652 fastq.gz 2.3 GB
EGAF00004838653 fastq.gz 2.2 GB
EGAF00004838654 fastq.gz 1.8 GB
EGAF00004838655 fastq.gz 1.9 GB
EGAF00004838656 fastq.gz 2.0 GB
EGAF00004838657 fastq.gz 2.0 GB
EGAF00004838658 fastq.gz 2.0 GB
EGAF00004838659 fastq.gz 1.9 GB
EGAF00004838660 fastq.gz 1.7 GB
EGAF00004838661 fastq.gz 1.7 GB
EGAF00004838662 fastq.gz 2.5 GB
EGAF00004838663 fastq.gz 2.4 GB
EGAF00004838664 fastq.gz 1.9 GB
EGAF00004838665 fastq.gz 1.9 GB
EGAF00004838666 fastq.gz 1.7 GB
EGAF00004838667 fastq.gz 1.7 GB
EGAF00004838668 fastq.gz 1.7 GB
EGAF00004838669 fastq.gz 1.6 GB
EGAF00004838670 fastq.gz 453.7 MB
EGAF00004838671 fastq.gz 458.4 MB
EGAF00004838672 fastq.gz 880.1 MB
EGAF00004838673 fastq.gz 884.6 MB
EGAF00004838674 fastq.gz 2.0 GB
EGAF00004838675 fastq.gz 2.0 GB
EGAF00004838676 fastq.gz 357.9 MB
EGAF00004838677 fastq.gz 360.5 MB
EGAF00004838678 fastq.gz 511.5 MB
EGAF00004838679 fastq.gz 512.9 MB
EGAF00004838680 fastq.gz 245.2 MB
EGAF00004838681 fastq.gz 245.3 MB
EGAF00004838682 fastq.gz 1.1 GB
EGAF00004838683 fastq.gz 1.1 GB
63 Files (76.7 GB)